Incyte Corporation
RUXOLITINIB FORMULATION FOR REDUCTION OF ITCH IN ATOPIC DERMATITIS
Last updated:
Abstract:
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Status:
Application
Type:
Utility
Filling date:
28 Mar 2022
Issue date:
8 Sep 2022